{"prompt": "['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 4 of 88', 'Table of Contents', 'TITLE PAGE', '2', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '16', '1', 'BACKGROUND AND RATIONALE', '18', '1.1', 'Medical background and short rationale for the clinical trial', '18', '1.2', 'Drug profile', '19', '1.3', 'Risk/benefit assessment', '19', '2', 'CLINICAL TRIAL OBJECTIVES AND CLINICAL HYPOTHESIS', '20', '2.1', 'Clinical trial objectives', '20', '2.2', 'Clinical hypotheses', '20', '3', 'OVERALL CLINICAL TRIAL DESCRIPTION', '21', '3.1', 'Efficacy assessment', '21', '3.2', 'Safety Assessment', '21', '3.3', 'Application areas', '21', '4', 'CLINICAL TRIAL DURATION AND TERMINATION', '23', '5', 'SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION', '23', '5.1', 'Number of subjects', '23', '5.2', 'Clinical trial population characteristics', '23', '5.3', 'Inclusion criteria', '23', '5.4', 'Exclusion criteria', '25', '5.5', 'Previous and concomitant therapies', '28', '5.5.1', 'Definition', '28', '5.5.2', 'Categories', '28', '5.5.3', 'Recording', '28', '5.5.4', 'Authorized concomitant therapies', '29', '5.5.5', 'Prohibited concomitant therapies', '29', '5.6', 'Procedures/reasons for subject discontinuation', '30', '6', 'CLINICAL SUPPLIES', '32', '6.1', 'Clinical supply identification and use', '32']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 5 of 88', '6.1.1', 'Study drug description', '32', '6.1.2', 'Subject identification number', '33', '6.1.3', 'Kit number', '33', '6.1.4', 'Instructions for use and application', '33', '6.1.5', 'Other supplies', '34', '6.2', 'Study drug packaging and labeling', '35', '6.3', 'Supplies management', '35', '6.3.1', 'Accountability', '35', '6.3.2', 'Storage of clinical study drug', '35', '6.3.3', 'Dispensing and return', '36', '6.3.4', 'Treatment compliance management and record', '36', '6.4', 'Dose modification', '37', '7', 'CLINICAL TRIAL ASSESSMENT', '37', '7.1', 'Efficacy assessments', '37', '7.1.1', 'Efficacy measurements', '37', '7.1.2', 'Efficacy endpoints', '40', '7.2', 'Safety assessment', '41', '7.2.1', 'Local tolerability assessment (of face and of trunk)', '41', '7.2.2', 'Adverse events', '42', '7.3', 'Other assessments', '51', '7.3.1', 'Photographs', '51', '7.3.2', \"Dermatology Life Quality Index (DLQI) / Children's Dermatology Life\", 'Quality Index (C-DLQI)', '52', '7.3.3', 'CompAQ for Facial and Truncal Acne', '53', '7.3.4', 'EuroQoL 5-Dimension (EQ-5D-5L)', '54', '7.3.5', 'Subject satisfaction questionnaire', '54', '7.3.6', 'Study drug acceptability questionnaire', '54', '8', 'CLINICAL TRIAL VISITS DESCRIPTIONS AND PROCEDURES', '54', '8.1', 'Description of clinical trial visits', '54']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 6 of 88', '8.1.1', 'Screening visit', '54', '8.1.2', 'Screening/Baseline visit', '55', 'CCI', '8.1.9', 'Unscheduled visits', '61', '8.2', 'Subject instructions (other than study drug administration)', '61', '9', 'STATISTICAL METHODS PLANNED', '62', '9.1', 'Statistical analysis plan', '62', '9.1.1', 'Data transformations', '62', '9.1.2', 'Populations analyzed, evaluability and limitation / evaluation of bias', '63', '9.1.3', 'Data presentation and graphics', '63', '9.2', 'Sample size determination', '65', '10', 'TRAINING / MONITORING / DATA MANAGEMENT / QUALITY ASSURANCE', '65', '10.1', 'Personnel training', '65', '10.2', 'Clinical monitoring', '65', '10.3', 'Data management', '66', '10.4', 'Quality assurance / audit / inspection', '66', '10.5', 'Changes in clinical trial conduct / amendments', '66', '10.5.1', 'Clinical trial conduct', '67', '10.5.2', 'Amendments', '67', '10.5.3', 'Attrition', '67', '11', 'ETHICS AND GENERAL CLINICAL TRIAL CONDUCT CONSIDERATIONS', '67', '11.1', 'Institutional Review Board or Independent Ethics Committee', '68', '11.2', 'Ethical conduct of the clinical trial', '68', '11.3', 'Subject information and consent', '68']\n\n###\n\n", "completion": "END"}